Try our Advanced Search for more refined results
Life Sciences
-
April 28, 2026
Chinese Man Extradited from Italy Over COVID Data Theft
A Chinese citizen has appeared before a Houston federal court after being extradited from Italy to face charges for his alleged role in the Microsoft "HAFNIUM" cyberattack that was allegedly orchestrated by the Chinese government to target U.S. COVID-19 research.
-
April 28, 2026
Hikma, Cipla Cut Deals In Pfizer Heart Drug Patent Case
Hikma Pharmaceuticals PLC and Cipla Ltd. have reached settlements with Pfizer Inc. in a case over the two defendants' efforts to create generic versions of the heart medication Vyndamax.
-
April 28, 2026
Maryland Justices Allow IVF Cost Class Action To Proceed
A Maryland couple can pursue a proposed class action against a health insurer that they say wrongfully denied coverage for embryo thawing in connection with an in vitro fertilization procedure, the Maryland Supreme Court has ruled, finding that the insurer's subsequent payment of the claim doesn't moot the suit.
-
April 28, 2026
Eli Lilly Inks $2.25B AI Genetics Research Pact With Profluent
AI-focused biotech Profluent said Tuesday it has entered a multiprogram, strategic research collaboration with Eli Lilly and Co. to treat diseases with high unmet need, in a deal that involves an upfront payment and up to $2.25 billion in additional milestone payments.
-
April 28, 2026
Meet The Attys Arguing The High Court 'Skinny Label' Case
When the U.S. Supreme Court hears arguments Wednesday in a patent case involving "skinny labels" on generic drugs, a longtime patent attorney as well as a government attorney who often handles intellectual property cases will face an appellate specialist who has argued many high court cases.
-
April 27, 2026
North Dakota Drug-Pricing Law Blocked In Pharma Fight
A North Dakota federal judge on Monday blocked the state's new drug-pricing law, agreeing with pharmaceutical companies that while the law purports to "protect the underdogs," it illegally interferes with the federal drug-pricing regime.
-
April 27, 2026
Did Hedge Fund 'Greed' Hurt Vaxart Investors? Jury To Decide
Armistice Capital and two of its executives used misleading press releases to pump and dump $250 million in Vaxart stock during the pandemic through misleading press releases in an act of pandemic-era "greed," investors' counsel told a California federal jury during closing arguments Monday, while the hedge fund defendants' lawyer countered Vaxart's announcements were "true and accurate."
-
April 27, 2026
DOJ Says Wash. 340B Drug Law Is Preempted In Novartis Suit
The U.S. Department of Justice waded into a dispute between pharmaceutical giants and the state of Washington on Monday, arguing that federal law preempts a new state law that expands discounts that drugmakers must provide under the federal 340B Drug Pricing Program.
-
April 27, 2026
High Court Appears Split In Monsanto Roundup Appeal
Monsanto's efforts to stem the tide of thousands of lawsuits over its blockbuster weedkiller Roundup seemed to find a mixed audience with the U.S. Supreme Court justices Monday as they debated the benefits of national labeling standards with how regulators stay on top of changing science.
-
April 27, 2026
Moderna Hit With Suit Over CureVac COVID Patents
BioNTech subsidiary CureVac has launched a new patent infringement suit against Moderna, claiming its COVID-19 vaccine infringed a handful of patents, saying the Massachusetts-based company "exploited" its messenger RNA technology.
-
April 27, 2026
Attys, Advocates Call DOJ Pot Rule Historic Shift For Feds
Legal strategies are evolving quickly in the wake of last week's "historic" rescheduling of state-legal medical cannabis, as a group of attorneys and advocates gathered Monday to evaluate the trade-offs of dispensaries now being able to register like pharmacies with the feds and the potential effect on industry investments and trade.
-
April 27, 2026
IQVIA Accuses Ex-Execs, Syneos Of Poaching $180M Client
IQVIA Holdings Inc. is accusing former executives of defecting to a competitor in the clinical research organization industry and initiating a corporate raid that resulted in the loss of one customer worth at least $180 million, according to a lawsuit filed in North Carolina Business Court.
-
April 27, 2026
4 Firms Build Astorg's $1.1B Microbiology Biz Buy
Life sciences company Thermo Fisher Scientific Inc. on Monday announced plans to sell its microbiology business to European private equity firm Astorg in an over $1.1 billion deal steered by four law firms.
-
April 27, 2026
3rd Circ. Panel Once Again Backs Talc Co. Whittaker's Ch. 11
The Third Circuit on Monday upheld its decision that Whittaker Clark & Daniels was authorized to file for Chapter 11 and certain claims against the defunct talc supplier's corporate successor belong to the debtor, not personal injury claimants.
-
April 27, 2026
Bioscience Co. Allegedly Hid Volatility Risks From Investors
A company purportedly focused on using traditional Chinese medicine to treat conditions including autism spectrum disorder faces a proposed investor class action alleging it downplayed the risk it would be probed in connection with unusual volatility affecting the market for its shares.
-
April 27, 2026
McCarter & English Plans New Waterfront Home In Boston
New Jersey-based McCarter & English LLP has chosen a new home for its Boston office, opting for a location in the middle of the city's downtown waterfront district, the firm has announced.
-
April 27, 2026
Catching Up With Delaware's Chancery Court
The Delaware Chancery Court this past week tackled a fresh mix of deal litigation, procedural disputes and fiduciary duty claims, with several rulings and filings underscoring the court's continued focus on contractual precision, forum enforcement and the limits of stockholder challenges.
-
April 27, 2026
What To Watch As Justices Take On 'Skinny Label' Case
The U.S. Supreme Court will hear arguments Wednesday on whether to permit a patent suit over a generic heart drug using a so-called skinny label, a case with ramifications for the drug industry that could shape patent disputes more broadly and other legal areas. Here's what to watch for.
-
April 27, 2026
Ropes & Gray, Cooley Lead Lilly's $2.3B Cancer Drug Buy
Eli Lilly and Co. said Monday it will acquire privately held Ajax Therapeutics in a deal worth up to $2.3 billion, as the drugmaker looks to expand its pipeline of treatments for blood cancers.
-
April 27, 2026
US, Indian Firms Guide $11.75B Sun Pharma-Organon Deal
Indian pharmaceutical giant Sun Pharmaceutical Industries Ltd. has agreed to acquire New Jersey-based Organon & Co. in an all-cash deal valued at $11.75 billion, with each side of the transaction having representation from one U.S. and one Indian law firm.
-
April 24, 2026
Up Last At High Court: TPS, Geofence, Skinny Labels
The U.S. Supreme Court will close out its oral argument portion of the 2025 October term by hearing a panoply of disputes over the constitutionality of geofence warrants, the existence of aiding and abetting torture claims, and the rescission of temporary protected status for hundreds of thousands of immigrants.
-
April 24, 2026
Natera Tells Justices CareDx Made Up Circ. Split In Petition
Natera asked the U.S. Supreme Court to reject a petition from rival CareDx asking it to review a Third Circuit decision that erased a $45 million jury verdict stemming from CareDx's false advertising claims, saying Friday the circuit split that CareDx claims exists is "imagined."
-
April 24, 2026
NY Court Pauses $100M Saudi Arabia Pharma Award Suit
A New York federal judge has paused litigation filed by a Qatari pharmaceutical distributor and its chairman aimed at enforcing a nearly $100 million arbitral award against Saudi Arabia while a hearing is conducted in the kingdom's set-aside petition in England next week.
-
April 24, 2026
What's At Stake As High Court Hears Roundup Appeal
With a $7.25 billion deal potentially at stake, Monsanto heads to the U.S. Supreme Court on Monday in its closely watched appeal of a $1.25 million jury verdict awarded to a Missouri man who claimed that Roundup weed killer caused his cancer.
-
April 24, 2026
Danaher Execs Face Investor Suit Over Post-COVID Outlook
Danaher Corp. executives are facing a proposed securities class action in Delaware federal court alleging they profited while misleading stockholders about the slowing sales of its diagnostics and bioprocessing products.
Editor's Picks
-
Supreme Court Will Tackle Patent Enablement In Amgen Case
The U.S. Supreme Court on Friday agreed to review Section 112 of the Patent Act for the second time in the law's history, accepting Amgen's request to consider how much a patent must disclose in order to meet enablement requirements.
-
A Circuit-By-Circuit Guide To FCA Suits After High Court Snub
The U.S. Supreme Court's refusal to resolve one of the False Claims Act's most consequential controversies leaves circuit courts deeply divided over whistleblower pleading obligations in ways that will reverberate nationwide, attorneys say. Here, Law360 explores each circuit's approach and scenarios that might finally trigger high court intervention.
-
Inside The Collapse Of A Pioneering Opioid Case For DOJ
The U.S. Department of Justice launched a "terribly flawed" criminal case against a drug distributor and several individuals amid pressure to alleviate Appalachia's opioid crisis, and a newly confirmed U.S. attorney displayed "courage and guts" by ending the case last month, defense counsel told Law360 in an expansive interview.
Expert Analysis
-
How The Coming Months Will Shape State Drug Price Boards
The future of state prescription drug affordability boards may be determined in the next few months, between an upcoming court decision in a challenge against state authority to set drug prices, and pending state decisions about whether to use federal Medicare maximum fair prices as reference, say Michael Kolber, Steven Chen and Kelechi Ezealaji at Manatt.
-
High Court 'Skinny Label' Case Will Matter To Tech Litigators
Hikma v. Amarin, set for oral argument in the U.S. Supreme Court on Wednesday, has potential to affect not just generic drug label-based evidence in patent cases, but also how technology inducement cases are presented and proven, says attorney Abdul Abdullahi.
-
How Food, Beverage Claims May Preview Cosmetic Litigation
Class action litigation targeting cosmetics and personal care products is accelerating, with a playbook that comes from the food and beverage industry — and the defenses that succeeded, and failed, in past class actions offer a critical road map for beauty and personal care brands, say attorneys at Crowell.
-
Court's HRSA Policy Reversal Leaves 340B Rules Murky
A D.C. federal court's recent decision in Premier v. U.S. Department of Health limits the Health Resources and Services Administration's ability to enforce long-standing Section 340B interpretations through subregulatory guidance, leaving open core statutory questions about purchasing models, inventory classification and program oversight, says Martha Cramer at Hooper Lundy.
-
Series
Officiating Football Makes Me A Better Lawyer
Though they may seem to have little in common, officiating football has sharpened many of the same skills that define effective lawyering in management-side labor and employment: preparation, judgment, composure, credibility and ability to make difficult decisions in real time, says Josh Nadreau at Fisher Phillips.
-
Fresenius Ruling May Shift Anti-Kickback Enforcement
The Ninth Circuit's recent decision in Fresenius v. Bonta suggests that businesses have a First Amendment right to donate to certain charities, even if those donations are motivated by economic self-interest, potentially calling into question years of Anti-Kickback Statute proceedings against pharmaceutical manufacturers for making similar donations, says Jonah Knobler at Patterson Belknap.
-
Written Consent Ruling May Signal Change For Telemarketing
The Fifth Circuit's ruling in Bradford v. Sovereign Pest Control is a takedown of the Federal Communications Commission's prior express written consent regulation, and because Loper Bright empowers courts to disregard agency interpretations, Telephone Consumer Protection Act litigants now have an opportunity to challenge previously settled FCC regulations, orders and interpretations, say attorneys at Manatt.
-
Series
Law School's Missed Lessons: How To Draft Pleadings
Most law school graduates step into their first jobs without ever having drafted a complaint, answer, motion or other type of pleading, but that gap can be closed by understanding the strategy embedded in every filing, writing with clarity and purpose, and seeking feedback at every step, says Eric Yakaitis at Haug Barron.
-
At The Fed. Circ., Means-Plus-Function Is Not Quite Dead
Recent Federal Circuit opinions confirm that means-plus-function claims continue to be drafted, issued, litigated and even infringed — but minding the restrictions imposed over the years by courts and statute requires three steps, says Jay Yates at Patterson & Sheridan.
-
E-Discovery Quarterly: Recent Rulings On ESI Control
Several recent federal court decisions have perpetuated a split over what constitutes “control” of electronically stored information — with judges divided on whether the standard should turn on a party's legal right or practical ability to obtain the information, say attorneys at Sidley.
-
Opinion
USPTO Should Let Inventors Valuate Patents In Prosecution
By building patent valuation into the application process, rather than waiting until potential litigation years down the line, the U.S. Patent and Trademark Office would streamline the process for inventors protecting and enforcing their patents, says John Powers at Powers IP.
-
2 Discovery Rulings Break With Heppner On AI Privilege Issue
While a New York federal court’s recent ruling in U.S. v. Heppner suggests that some litigants’ communications with AI tools are discoverable, two other recent federal court decisions demonstrate that such interactions generally qualify for work-product protection under the Federal Rules of Civil Procedure, says Joshua Dunn at Brown Rudnick.
-
Series
Isshin-Ryu Karate Makes Me A Better Lawyer
My involvement in martial arts, specifically Isshin-ryu, which has principles rooted in the eight codes of karate, has been one of the most foundational in the development of my personality, and particularly my approach to challenges — including in my practice of law, says Kaitlyn Stone at Barnes & Thornburg.
-
Microplastics On Water Contaminant List Could Spur Claims
The U.S. Environmental Protection Agency's proposal to include microplastics in its draft sixth Contaminant Candidate List under the Safe Drinking Water Act could influence consumer fraud claims and enforcement by state attorneys general, as well as claims against manufacturers from entities facing regulatory compliance costs, says Arie Feltman-Frank at Jenner & Block.
-
USPTO's AI Search Pilot May Reshape Patent Filing Strategy
The U.S. Patent and Trademark Office's new artificial intelligence search pilot aims to introduce earlier visibility into the prior art landscape, potentially influencing patent filing considerations and shifting the role of counsel to an earlier stage of the prosecution process, say attorneys at Foley & Lardner.